DE60027581D1 - Design von immunogene - Google Patents

Design von immunogene

Info

Publication number
DE60027581D1
DE60027581D1 DE60027581T DE60027581T DE60027581D1 DE 60027581 D1 DE60027581 D1 DE 60027581D1 DE 60027581 T DE60027581 T DE 60027581T DE 60027581 T DE60027581 T DE 60027581T DE 60027581 D1 DE60027581 D1 DE 60027581D1
Authority
DE
Germany
Prior art keywords
response
immunogen
virus
type
immunogenese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60027581T
Other languages
English (en)
Other versions
DE60027581T2 (de
Inventor
Christopher Jones
Andrew Bacon
Gill Douce
Mark Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Celltech Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9923902.2A external-priority patent/GB9923902D0/en
Priority claimed from GB0007789A external-priority patent/GB0007789D0/en
Application filed by Medeva Europe Ltd, Celltech Pharma Europe Ltd filed Critical Medeva Europe Ltd
Publication of DE60027581D1 publication Critical patent/DE60027581D1/de
Application granted granted Critical
Publication of DE60027581T2 publication Critical patent/DE60027581T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE60027581T 1999-10-08 2000-10-06 Design von immunogene Expired - Fee Related DE60027581T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9923902 1999-10-08
GBGB9923902.2A GB9923902D0 (en) 1999-10-08 1999-10-08 T-helper cell responses to proteins
GB0007789A GB0007789D0 (en) 2000-03-30 2000-03-30 Designing immunogens
GB0007789 2000-03-30
PCT/GB2000/003857 WO2001027281A1 (en) 1999-10-08 2000-10-06 Designing immunogens

Publications (2)

Publication Number Publication Date
DE60027581D1 true DE60027581D1 (de) 2006-06-01
DE60027581T2 DE60027581T2 (de) 2007-05-10

Family

ID=26243998

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027581T Expired - Fee Related DE60027581T2 (de) 1999-10-08 2000-10-06 Design von immunogene

Country Status (7)

Country Link
US (1) US20040106174A1 (de)
EP (1) EP1218514B1 (de)
JP (1) JP2003511075A (de)
AT (1) ATE324448T1 (de)
AU (1) AU7546500A (de)
DE (1) DE60027581T2 (de)
WO (1) WO2001027281A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200201077A1 (ru) * 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед Коровые антигенные химерные белки гепатита в
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
ES2834072T3 (es) 2012-06-11 2021-06-16 Univ Xiamen Polipéptidos y anticuerpos para el tratamiento de la infección por vhb y enfermedades relacionadas
CN114729010A (zh) * 2019-08-29 2022-07-08 维尔生物科技有限公司 乙型肝炎病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
WO1994001132A1 (en) * 1992-07-07 1994-01-20 Merck & Co., Inc. VACCINE COMPRISING MIXED preS1+preS2+S AND CORE PARTICLE
EA200201077A1 (ru) * 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед Коровые антигенные химерные белки гепатита в
DK1294893T3 (da) * 2000-06-22 2006-07-03 Ucb Pharma Ltd Modifikation af hepatitis B-kerneantigen
US6896944B2 (en) * 2001-06-29 2005-05-24 3M Innovative Properties Company Imaged articles comprising a substrate having a primed surface
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030198645A1 (en) * 2002-02-21 2003-10-23 Mark Page Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis

Also Published As

Publication number Publication date
WO2001027281A1 (en) 2001-04-19
JP2003511075A (ja) 2003-03-25
US20040106174A1 (en) 2004-06-03
EP1218514A1 (de) 2002-07-03
ATE324448T1 (de) 2006-05-15
AU7546500A (en) 2001-04-23
EP1218514B1 (de) 2006-04-26
DE60027581T2 (de) 2007-05-10

Similar Documents

Publication Publication Date Title
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
NO20063026L (no) Antistoffer
ATE517909T1 (de) Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE60238541D1 (de) Modifizierte transferrin-fusionsproteine
ATE500323T1 (de) Subtilisin-variante
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
DE60027581D1 (de) Design von immunogene
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
ES2145742T3 (es) Uso de una proteasa de herpes.
DK1501936T3 (da) Familie af cytokin-proteiner
Mayor et al. Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
DK1374895T3 (da) Farmaceutisk sammensætning af F(AB) 2-fragmenter af antistoffer og fremgangsmåde til fremstilling heraf
WO2001004143A3 (en) Prostase vaccine
BR0016289A (pt) Vìrus sentinela i do vìrus da hepatite
AUPQ661600A0 (en) A nucleic acid construct and methods related thereto
DE60034243D1 (de) Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee